CRISPR-Cas systems: Challenges and future prospects

Nisarg Gohil; Gargi Bhattacharjee; Navya Lavina Lam; Samuel D Perli; Vijai Singh

doi:10.1016/bs.pmbts.2021.01.008

CRISPR-Cas systems: Challenges and future prospects

Prog Mol Biol Transl Sci. 2021:180:141-151. doi: 10.1016/bs.pmbts.2021.01.008. Epub 2021 Feb 15.

Authors

Nisarg Gohil¹, Gargi Bhattacharjee¹, Navya Lavina Lam², Samuel D Perli², Vijai Singh³

Affiliations

¹ Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India.
² The J. David Gladstone Institutes, San Francisco, CA, United States.
³ Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India. Electronic address: vijaisingh15@gmail.com.

PMID: 33934835
DOI: 10.1016/bs.pmbts.2021.01.008

Abstract

The advancement gained over the past couple of decades in clustered regularly interspaced short palindromic repeats and CRISPR associated proteins (CRISPR-Cas) systems have revolutionized the field of synthetic biology, therapeutics, diagnostics and metabolic engineering. The technique has enabled the process of genome editing to be very precise, rapid, cost-effective and highly efficient which were the downfalls for the previously debuted zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) technologies. However, despite its great potential, challenges including off-target activity, method of delivery, ethical and regulatory issues still remain unresolved for the CRISPR-Cas systems. In this chapter, we present and point out the obstacles faced in implementation of the CRISPR-Cas system along with its future prospects.

Keywords: CRISPR-Cas9; Challenges; Delivery; Gene editing; Off-target.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems* / genetics
Gene Editing*
Humans
Synthetic Biology
Transcription Activator-Like Effector Nucleases

Substances

Transcription Activator-Like Effector Nucleases